Alterity Therapeutics, a biotechnology company focusing on neurodegenerative diseases, announced its participation in the International Congress of Parkinson’s Disease and Movement Disorders, scheduled for September 27 – October 1, 2024, in Philadelphia. The company will present multiple oral and poster presentations, including late-breaking interim data from its ATH434-202 trial and baseline characteristics from its ATH434-201 Phase 2 trial. ATH434, Alterity's lead candidate, is an oral agent aimed at inhibiting the aggregation of pathological proteins implicated in neurodegeneration, such as α-synuclein, and has shown promise in preclinical studies. The ATH434-202 trial is an open-label study assessing the impact of ATH434 on neuroimaging and protein biomarkers in advanced Multiple System Atrophy (MSA) patients, with final data expected in the first half of 2025. The ATH434-201 trial is a randomized, double...Show More

Alterity Therapeutics, a biotechnology company focusing on neurodegenerative diseases, announced its participation in the International Congress of Parkinson’s Disease and Movement Disorders, scheduled for September 27 – October 1, 2024, in Philadelphia. The company will present multiple oral and poster presentations, including late-breaking interim data from its ATH434-202 trial and baseline characteristics from its ATH434-201 Phase 2 trial. ATH434, Alterity's lead candidate, is an oral agent aimed at inhibiting the aggregation of pathological proteins implicated in neurodegeneration, such as α-synuclein, and has shown promise in preclinical studies. The ATH434-202 trial is an open-label study assessing the impact of ATH434 on neuroimaging and protein biomarkers in advanced Multiple System Atrophy (MSA) patients, with final data expected in the first half of 2025. The ATH434-201 trial is a randomized, double-blind, placebo-controlled study in early-stage MSA patients, aiming to evaluate the efficacy of ATH434 over a 12-month treatment period. ATH434 has received Orphan drug designation for MSA treatment by the U.S. FDA and the European Commission. The company's participation in the congress is a significant opportunity to showcase its progress and findings in the development of treatments for MSA and Parkinsonian disorders.